REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin MaterialImmunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190043 - Use of a topical medicament comprising riluzole The present invention relates to the use of Riluzole if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Riluzole and use thereof. ... 08/09/07 - 20070184047 - Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction A method and composition for inhibiting phagocytosis of blood cells. The method involves providing a nitrophenyl compound or thimerosal with administration of the compound to a host having an auto or alloimmune disease to inhibit phagocytosis of blood cells. ... 07/26/07 - 20070172474 - Dairy components effective for fat loss The present invention relates to methods comprising administering to an individual regulating body weight calcium-containing whey products in an amount effective to maintain muscle mass, induce weight and/or fat loss, prevent weight and/or fat gain, and/or increase the metabolic consumption of adipose tissue in the individuals. ... 07/05/07 - 20070154468 - Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections The invention teaches the application of monoclonal antibodies being specific for CD28 and activating T lymphocytes of several to all sub-groups without occupying an antigen receptor of the T lymphocytes and thus in an antigen-unspecific manner, or an analogue thereto, for producing a pharmaceutical composition in an embodiment as a ... 06/07/07 - 20070128183 - Td antigens The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from enteroaggregative E. coli, enterotexigenic E. coli, S. flexneri and C. jejuni, methods for isolating such antigens and specific uses thereof. ... 03/29/07 - 20070071742 - Humanized antibodies Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID ... 03/01/07 - 20070048297 - Human secreted proteins The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, ... 02/22/07 - 20070041963 - Human secreted proteins The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, ... 02/15/07 - 20070036780 - Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are ... 02/15/07 - 20070036779 - Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form This invention is related to a stabilising formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilization of immunoglobulins G compositions in liquid form and in lyophilised form. The invention also relates to an immunoglobulins G composition in liquid form ... 02/15/07 - 20070036778 - S. epidermidis antigens The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. epidermidis, methods for isolating such antigens and specific uses thereof. ... 02/08/07 - 20070031403 - Interferon-gamma inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-γ inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating ... 02/08/07 - 20070031402 - Immunoconjugate formulations The present invention provides an immunoconjugate formulation that is substantially free of particles, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of: sucrose, polysorbate 20, polysorbate 80, cyclodextrin, dextrose, glycerol, polyethylene glycol, mannitol, sodium chloride, and an amino acid, wherein the formulation ... 02/01/07 - 20070025983 - Compounds capable of inhibiting hiv-1 infection This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to ... 02/01/07 - 20070025982 - Dna vaccines encoding antigen linked to a domain that binds cd40 Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto ... 02/01/07 - 20070025981 - Microorganisms for therapy Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also ... 02/01/07 - 20070025980 - Composition permitting muscle growth while protecting joint health A composition which helps reduce joint inflammation and structural damage to joints during the growth of muscle structure, whether such growth is for repair of damaged muscle tissue or for development of new and enhanced muscular structure. The composition comprises a combination of edible nutritional protein, and a hyperimmune milk ... 01/25/07 - 20070020255 - Method of stabilizing antibody and stabilized solution-type antibody preparation The present invention provides a method of suppressing the formation of a soluble association of an antibody in a solution; a method of suppressing the formation of a chemically degraded product of an antibody in a solution; and a method of stabilizing an antibody in a solution. The present invention ... 01/18/07 - 20070014784 - Methods and systems for treating injured cardiac tissue Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing ... 12/07/06 - 20060275283 - Fcgamma receptor-binding polypeptide variants and methods related thereto The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according ... 12/07/06 - 20060275282 - Antibodies and fc fusion proteins with altered immunogenicity Variant antibodies and Fc fusion proteins with reduced immunogenicity are described. In particular, the variants of antibodies and Fc fusion proteins have reduced ability to bind one or more human class II MHC molecules are described. ... 11/16/06 - 20060257393 - Method for protecting thiol group of protein A method for protecting a thiol group in a protein having a free cysteine residue, which comprises adding a compound which has a disulfide bond in the molecule and exerts substantially no influence on the activity of the protein. ... 10/26/06 - 20060239997 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 10/26/06 - 20060239996 - Antibodies specific for ungulate prp The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrPC and/or a denatured ungulate PrPSc, but not to a native ungulate PrPSc. Preferred antibodies find native bovine PrPC and treated PrPSc but not native bovine PrPSc and can be used ... 10/19/06 - 20060233786 - Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation Formulations for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient; and formulations for neutralizing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human ... 10/19/06 - 20060233785 - Immunointeractive molecules and uses thereof The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having latex allergy and genetic sequences encoding the same. These molecules are preferentially immunointeractive with T cells in subjects having a Hev b 6 allergy. The present invention also ... 10/05/06 - 20060222642 - Compositions for the treatment of mycobacterial infections The invention relates to the field of immunology and, more specifically, to the treatment of infectious diseases caused by mycobacteria, whereby antibody compositions are administered mucosally and in other ways for the prophylactic and therapeutic treatment of said diseases. The invention relates to the preparation of compositions of human antibodies ... 09/21/06 - 20060210554 - Detection of cholesterol ozonation products The invention relates to detection of cholesterol ozonation products that are generated by atherosclerotic plaque material, and to methods of detecting vascular conditions that relate to the accumulation and oxidation of cholesterol. ... 09/07/06 - 20060198839 - Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions Type 1 diabetes mellitus and other conditions relating to inadequate insulin or diminished levels of insulin can be treated by administering a pancreatic islet cell regeneration agent and/or an agent that transforms pancreatic ductal cells to islet cells in combination with administration of an agent that selectively inhibits, blocks, or ... 08/31/06 - 20060193847 - Peptides for inhibiting retroviruses Peptides derived from shark immunoglobulin preparations are used to prepare compositions, including pharmaceutical compositions, for inhibiting retrovirus replication in susceptible cells. The peptide preparations are useful for inhibiting diseases associated with retroviral infection, such as acquired immunodeficiency syndrome. The peptides also inhibit growth of tumor cells, especially sarcomas and leukemias. ... 08/17/06 - 20060182739 - Protein purification A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants. ... 08/17/06 - 20060182738 - Medical device for analyte monitoring and drug delivery The invention relates to an ingestible, implantable or wearable medical device comprising a microarray which comprises a bioactive agent capable of interacting with a disease marker biological analyte; a reservoir which comprises at least one therapeutic agent and is capable of releasing the therapeutic agent(s) from the medical device; and ... 06/22/06 - 20060134098 - Immunoglobulin variable region cassette exchange The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the VH and VL sequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of ... 06/08/06 - 20060121020 - Mixture preparation for enhancing absorption of immunoglobulins in postnatal domestic mammals, and the method thereof Disclosed is a mixture preparation containing an addition of selenium for enhancing absorption of immunoglobulins administered to postnatal domestic mammals (e.g., bovine), and the method thereof. As an example of a selenium compound added, sodium selenite is particularly effective. Further, the mixture preparation may contain raw milk, colostrum and/or cheese ... 04/20/06 - 20060083735 - Antigen-presenting complex-binding compositions and uses thereof A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed. ... 04/06/06 - 20060073138 - Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods The invention provides a novel gene, gridlock, and its encoded protein. gridlock plays a role in vascular development and modeling, and a mutation in gridlock has been associated with an aortic arch disease, coarctation. Thus, gridlock nucleic acid molecules and polypeptides can be used in methods of diagnosing, treating, and ... 04/06/06 - 20060073137 - Humanised antibodies CDR-grafted antibody heavy and light chain comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise ... 04/06/06 - 20060073136 - Humanised antibodies CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise ... 04/06/06 - 20060073135 - Methods and compositions for modulating and detecting wisp activity Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are pronided. WISP-1 antagonists inlcude anti-WISP-1 antiboties, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of IIAS2, IIA, CD4 or RIIAMM by native human WISP-1 polypeptide in at least one ... 04/06/06 - 20060073134 - Human diabetes-mediating proteins Provided are human secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating proteins, and methods of preventing or ameliorating diabetes by administering a compound capable ... 04/06/06 - 20060073133 - Sialoadhesin factor-3 antibodies Monoclonal antibodies have been generated that bind to human sialoadhesion factor-3. These antibodies are useful as diagnostic and therapeutic reagents. ... 03/23/06 - 20060062779 - Methods and compositions relating to mannuronic acid specific binding peptides The invention relates to compositions and methods relating to a protective alginate epitope and binding partners thereof. ... 03/23/06 - 20060062778 - Antibody buffering of a ligand in vivo Compositions and methods are provided in embodiments directed to maintaining a desired concentration range of one or more drugs in a subject, and in particular embodiments to maintaining a desired drug concentration in a body compartment in a subject, based on the surprising discovery that antibodies persist in solution in ... 03/23/06 - 20060062777 - Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and beta1 integrins Antagonists for modifying protein-protein interactions involving certain amino acid sequences within MMP-9 and/or β1 integrins are described. Such antagonists inhibit angiogenesis, tumor growth and disease states. Example antagonists are polypeptide and non-polypeptide molecules, including the novel antibody Mab FM155 and the novel synthetic peptide FRIP-1. Methods for inhibiting angiogenesis and ... 03/16/06 - 20060057135 - Mucosal vascular addressins and uses thereof The present invention relates to pharmaceutical compositions which comprise an antibody and/or antigen-binding fragments which have the epitopic specificity of ACT-1 monoclonal antibody. ... 03/16/06 - 20060057134 - Antibody against antibacterial peptide and utiliazation thereof An antibody which binds to a “peptide consisting of the amino acid sequence represented by SEQ ID NO:1”, and a method for assaying a “peptide comprising the amino acid sequence represented by SEQ ID NO:1” in a sample and a method for detecting a bacterial pneumonia, wherein the methods use ... 03/09/06 - 20060051342 - Carrier having immobilized antigens or antibodies and method of manufacturing thereof Carrier and method of its manufacture having immobilized antigens or antibodies, including a carrier having a surface, in which at least the surface of the carrier is formed of a calcium phosphate based compound; antiligands provided on and surrounding the surface of the carrier; a blocking layer formed of a ... 02/16/06 - 20060034831 - Combination therapy for diabetes, obesity and cardiovascular diseases using gdf-8 inhibitors A method of treating obesity, cardiovascular diseases, and disorders of insulin metabolism in a subject, comprising administering to the subject a therapeutically effective amount of a GDF-8 inhibitor, and a therapeutically effective amount of at least one other therapeutic agent which treats the targeted syndrome. ... 02/16/06 - 20060034830 - Immunoglobulins comprising predominantly a galglcnacman5glcnac2 glycoform The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GalGlcNAcMan5GlcNAc2. ... 02/16/06 - 20060034829 - Immunoglobulins comprising predominantly a man3glcnac2 glycoform The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man3GlcNAc2. ... 02/16/06 - 20060034828 - Immunoglobulins comprising predominantly a glcnacman5glcnac2 glycoform The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GlcNAcMan5GlcNAc2. ... 02/16/06 - 20060034827 - Stabilized liquid anti-rsv antibody formulations The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, ... 02/16/06 - 20060034826 - Use of agents that modulate the interaction between pd-1 and its ligands in the downmodulation of immune responses Disclosed are methods for downmodulating an immune response comprising contacting all immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1), to thereby modulate the immune response. ... 02/09/06 - 20060029596 - Replication-competent anti-cancer vectors Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are ... 02/09/06 - 20060029595 - Methods of using human receptor protein 4-1bb Disclosed herein are the methods of using the H4-1BB protein, ligands to this protein, and various mAbs either directed against H4-1BB or other molecules that can be used therapeutically. The nature and importance of the H4-1BB molecule provides the ligands and related co-stimulatory molecules the ability to enhance or suppress ... 02/09/06 - 20060029594 - Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided. ... 02/09/06 - 20060029593 - Humanised antibodies CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise ... 02/02/06 - 20060024294 - Compositions for prevention and treatment of infections caused by parasites in animals The invention refers to anticoccidial compositions consisting mainly of yolk immunoglobulins derived from eggs of hens immunized with one or more Eimeria species. The invention refers also to the use of said anticoccidial compositions for prevention or treatment of coccidiosis. The administration of immunoglobulins, both in liquid as well as ... 02/02/06 - 20060024293 - Human antibodies that bind human tnfalpha Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in ... 02/02/06 - 20060024292 - Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Gal2GlcNAc2Man3GlcNAc2 lacking fucose. ... 02/02/06 - 20060024291 - Protocadherin materials and methods Polynucleotide sequences encoding novel cadherin-like polypeptides, designated protocadherins, and variants thereof are provided by the invention as well as methods and materials for the recombinant production of the same. Antibody substances specific for protocadherins are also disclosed as useful for modulating the natural binding and/or regulatory activities of the protocadherins. ... 02/02/06 - 20060024290 - Immunogenic lhrh compositions and methods relating thereto The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns ... 01/26/06 - 20060018898 - Antibody variants This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable ... 01/26/06 - 20060018897 - Bispecific antibodies The present invention provides compositions and methods for targeting stem cells to injured cardiac tissue. ... 01/26/06 - 20060018896 - Methods for treating conditions associated with lectin-dependent complement activation In one aspect, the invention provides methods of inhibiting the effects of lectin-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation. In some embodiments, the MAp19 ... 01/26/06 - 20060018895 - Murine monoclonal anti-idiotype antibody 11d10 and methods of use thereof The present invention provides a monoclonal anti-Idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological ... 01/19/06 - 20060013808 - Treatment for asthma A method for the treatment of asthma is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a protein expressed on the surface of certain leukocytes such as eosinophils. ... 01/05/06 - 20060002919 - 15625 receptor, a novel g-protein coupled receptor The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further ... 12/22/05 - 20050281808 - Peptide fragments having cell death-inhibitory activity The present invention provides a peptide fragment or a series of peptide fragments having a cell death-inhibitory activity, having the amino acid sequence consisting of 103 amino acid residues at the C-terminal of selenoprotein P, or having said amino acid sequence with one or several amino acid residues therein being ... 12/22/05 - 20050281807 - Use of c-reactive protein to treat immune complex-mediated renal disease The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus. ... 12/15/05 - 20050276797 - Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease. ... 12/08/05 - 20050271650 - Method and composition for angiogenesis inhibition The invention features methods and compositions for inhibiting angiogenesis in a tissue or detecting angiogenesis using antagonists of denatured or proteolyzed forms of laminin. ... 12/08/05 - 20050271649 - Therapeutic adjuvant Disclosed are methods for enhancing an immune response associated with a disease or condition in a patient comprising administering a first composition comprising a non-specific xenotypic antibody and optionally further administering a second composition comprising a specific xenotypic antibody that specifically binds to an antigen associated with the disease or ... 12/01/05 - 20050265992 - F11 receptor (f11r) antagonists as therapeutic agents The present invention provides a cell adhesion molecule (CAM), designated F11 receptor (F11R), which is a member of the immunoglobulin super family localized on the surface of human platelets, and determined to effect platelet aggregation, secretion, platelet spreading and cellular adhesion. F11R-antagonists and methods for the prevention and treatment of ... 12/01/05 - 20050265991 - Drug delivery apparatus utilizing cantilever Disclosed is a device which employs a chemically sensitive cantilever hingably attached to a capsule. The cantilever functions as a switch which regulates the flow of particles into and/or out of the capsule. ... 11/24/05 - 20050260193 - Steroid sparing agents and methods of using same This invention relates generally to methods of treating inflammatory bowel diseases (IBD), asthma, Crohn's Disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient ... 11/24/05 - 20050260192 - Modified polypeptides stabilized in a desired conformation and methods for producing same The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock ... 11/24/05 - 20050260191 - Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (pth) 1-84 Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH ... 11/24/05 - 20050260190 - Therapeutic agent for inos generating illness A therapeutic agent which removes or neutralizes iNOS in the blood of a mammalian subject. The agent may be in the form of an anti-iNOS monoclonal antibody or an INOS binding entity. ... 11/24/05 - 20050260189 - Microbubble compositions, and methods for preparing and using same Described are microbubble compositions including microbubbles having membranes that incorporate modified surface features that may be useful, for example, in facilitating binding to a target surface or substance. The surface features may include non-spherical attributes such as crenations, folds, projections, or wrinkles, which can increase the deformability of the microbubble ... 11/17/05 - 20050255098 - Methods of treating traumatic spinal cord injury The present invention provides methods of treating traumatic spinal cord injury, methods of reducing cell-mediated demyelination of long descending fiber tracts or local circuits in the spinal cord following traumatic spinal cord injury, and methods for improving or restoring locomotor recovery and/or fine motor movement in an individual following spinal ... 11/10/05 - 20050249721 - Compositions and methods for targeted biological delivery of molecular carriers The present invention relates to compositions and methods for the delivery of biologically-relevant moieties to subjects in need thereof. Particles comprising a physically entrapped targeting moiety, or a moiety that binds thereto, can promote paracellular transport, active transport, endocytosis or transcytosis into, through, out of and around, cells, tissues, and ... 11/03/05 - 20050244404 - Methods of donor specific crossmatching The detection of endothelial cell antibodies has been proven clinically important for successful organ transplantation. Disclosed are methods of isolating endothelial cell antibodies for donor-specific crossmatching. ... 11/03/05 - 20050244403 - Immunoglobulin variants outside the fc region The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. ... 11/03/05 - 20050244402 - Absorption of pain-causing agents There is provided a pain relieving substance made of an eicosanoid-absorbent substance and a carrier. The eicosanoid-absorbent substance may be an eicosanoid enzyme, antibody and/or acid moiety binder. The eicosanoids may be prostaglantins, thromboxanes, leukotrienes, lipoxins and hydroxyl and hydroperoxy fatty acids and mixtures thereof. The eicosanoid-absorbent substance may be ... 10/27/05 - 20050238639 - Use of relaxin to increase arterial compliance The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides ... 10/20/05 - 20050232916 - Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor The present invention provides methods for determining or identifying compounds that modulate the function of an isolated retinal pericyte or blood vessel, wherein a change in the contractile state of said pericyte or blood vessel is determined in the presence of a test compound, said change indicating that the test ... 10/13/05 - 20050226862 - Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders and for identifying agents therapeutic therefor Methods and compositions are disclosed that are useful for the prevention and/or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic/reperfusion damage in humans; and cardiovascular trauma. The beneficial effects of the compositions and methods are achieved ... 10/13/05 - 20050226861 - Immunogen adherence inhibitor and method of making and using same A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor ... 10/06/05 - 20050220784 - Quinazoline derivatives as medicaments each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents. ... 10/06/05 - 20050220783 - Antibody production in farm animals The present invention provides means and methods for obtaining an antibody in a mammary secretion product of a farm-animal comprising administering to said animal at least two compositions, which may be the same or different, comprising an antigen to which said antibody is to be raised, the method comprising administering ... 09/29/05 - 20050214278 - Antibody-containing solution pharmaceuticals Antibody-containing solution formulations including a sugar as a stabilizer. Said solution formulations can further include a surfactant as a stabilizer. ... 09/22/05 - 20050208040 - Polynucleotides and polypeptides encoded thereby The invention provides polypeptides, designated herein as PROX polypeptides, as well as polynucleotides encoding PROX polypeptides, and antibodies that immunospecifically-bind to PROX polypeptide or polynucleotide, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which the PROX polypeptide, polynucleotide, and antibody are used in the detection, ... 09/22/05 - 20050208039 - Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, ... 09/15/05 - 20050202003 - Methods for sterilizing preparations of monoclonal immunoglobulins Methods are disclosed for sterilizing preparation of monoclonal immunoglobulins to reduce the level of active biological contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas, prions and parasites. ... 09/01/05 - 20050191289 - Complexes of immunoglobulins and polysaccharides for oral and transmucosal absorption The present invention relates to complexes consisting of immunoglobulins and polysaccharides for oral and transmucosal use. The polysaccharides comprised in the complexes according to the invention form an envelope which protects and carries immunoglobulins allowing their systemic absorption through the gastric and mucosal district. Immunoglobulins have a different specificity depending ... 08/25/05 - 20050186200 - Hadhs as modifiers of the p21 pathway and methods of use Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided. ... 08/25/05 - 20050186199 - Compositions and methods for detecting stress-inducible proteins Compositions and methods for detection of the stress-inducible Hsp70B′ protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B′ and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B′ antibodies to defined epitopes permits a variety of in vitro and in ... 08/18/05 - 20050180968 - Use of relaxin for stimulating the development of activated human t cells into th1-like effectors Relaxin (RLX) is shown to be effective in stimulating the development of activated human T cells into Th1-like effectors, for counteracting Th2-dominated disorders and for regulating immune homeostasis during pregnancy. Methods are contemplated of administering RLX or a derivative thereof to a human patient to treat a Th2-dominated disease, such ... 08/18/05 - 20050180967 - Polyclonal antibody composition for treating allergy A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as ... 08/11/05 - 20050175602 - Methods for heat-stabilizing proteins with specific binding activities It is disclosed here that a protein with a heat-labile specific binding activity can be stabilized with a saccharide compound with regard to the binding activity. To heat-stabilize the protein, it is mixed with a saccharide compound in a liquid suspension and the suspension is then dried to produce a ... 08/04/05 - 20050169913 - Compositions comprising antibodies to human fgi2 Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, ... 08/04/05 - 20050169912 - Immunogenic peptides and uses thereof Novel general methods and compositions provide specific or highly associated antigenic peptides useful for diagnosis and treatment of diseases caused by microorganisms, allergens or other proteins. Specific or highly associated peptide antigens are also useful for diagnosis, treatment and prevention of auto-immune diseases, allergens and other diseases. ... 08/04/05 - 20050169911 - Monoclonal antibody recognizing phosphatidylinositol-3,4,5-triphosphate A novel monoclonal antibody that specifically recognizes phosphatidylinositol-3,4,5-triphosphate (PIP3) but does not cross-react with structurally similar phospholipid antigens is advantageous for PIP3-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies. ... 08/04/05 - 20050169910 - Growth blocking agents There is disclosed anti-receptor and growth blocking agents to the vitamin B12/transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B12, thus inhibiting cell division or causing apoptosis. Anti-receptor and growth ... 08/04/05 - 20050169909 - Identification of novel ige epitopes The present invention relates to novel peptide epitopes derived from the CH3 domain of IgE which are recognized by high affinity antibodies that specifically bind IgE. These novel peptides may be used for both active immunization of a subject by administering these peptides to generate high affinity antibodies in a ... 07/28/05 - 20050163767 - Novel protein and dna thereof The protein of the present invention and a DNA encoding the same can be used as therapeutic/prophylactic agents for diseases such as infectious diseases. The protein of the present invention is also useful as a reagent for screening a compound or its salt capable of promoting or inhibiting the activity ... 07/28/05 - 20050163766 - Secreted and transmembrane polypeptides and nucleic acids encoding the same The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides ... 07/14/05 - 20050152892 - Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutics uses The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the Cε3 or Cε4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis ... 07/07/05 - 20050147602 - Compositions, methods and kits relating to cthrc1, a novel modulator of collagen matrix The invention relates to a novel CTHRC1 nucleic acid and protein encoded thereby. Expression of CTHRC1 is induced by injury in, among others, arteries and skin, and CTHRC1 is expressed in bone, cartilage, kidney, lung and brain. CTHRC1 expression is associated with collagen matrix production, arterial remodeling, arterial restenosis, constrictive ... 06/23/05 - 20050136048 - Assay buffer, compositions containing the same, and methods of using the same Compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the invention relates to the use of novel combinations of reagents to provide improved assay performance. ... 06/23/05 - 20050136047 - Hapten-carrier conjugates for treating and preventing nicotine addiction Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates ... 06/16/05 - 20050129679 - Method for opening tight junctions The use of antagonists to JAM-1 Claudin-4 and occludin to open tight junctions. The antagonists include, by way of example antibodies and antibody fragments that bind to the proteins and small interfering nucleic acids that downregulate the mRNA encoding the proteins. ... 06/16/05 - 20050129678 - Method for the prediction of an epitope The invention provides methods for the prediction of an epitope in a target protein. An epitope of the target protein can be bound by a given molecule, e.g., by an antibody. In particular, the methods of the invention comprise (i) identifying a plurality of cross-reactive proteins, i.e., proteins that can ... 06/16/05 - 20050129677 - Lipid rafts and clostridial toxins The present invention is directed to methods of altering the degree of internalization of a Clostridial toxin; methods of preventing or treating botulinum toxin intoxication; methods of treating metabolic disorders, muscular disorders, nervous system disorders, and/or pain conditions; methods of inhibiting the formation of lipid rafts on cell membranes; methods ... 06/16/05 - 20050129676 - Compounds and methods for modulating functions of classical cadherins Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion ... 06/09/05 - 20050123534 - Humanised antibodies CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise ... 06/09/05 - 20050123533 - Prodrugs activated by targeted catalytic proteins Disclosed and claimed are prodrugs activated by catalytic proteins, such as enzymes and catalytic antibodies. The invention comprehends such prodrugs, as well as haptens, to elicit catalytic antibodies to activate the prodrugs. The prodrugs are useful as cytotoxic chemotherapeutic agents; e.g., as antitumor agents. ... 06/09/05 - 20050123532 - Method of activating protein A method of producing a protein having free cysteine with the use of a serum-free medium, characterized in that the protein is produced in the activated state; a method of producing a protein by culturing in a serum-free medium in accordance with the above method; a method of activating a ... 06/02/05 - 20050118163 - Antibody-containing solution pharmaceuticals An antibody-containing solution formulation comprising an organic acid and a surfactant as stabilizers; a method for suppressing the formation of visible insoluble matter and/or insoluble particles due to the presence of metal ions in an antibody-containing solution formulation, which comprises adding an organic acid to the solution; a method for ... 06/02/05 - 20050118162 - Treatment of micro-organism infection The present invention is concerned with novel antibodies, medicaments, pharmaceutical packs, methods of manufacture of medicaments and methods for the treatment of micro-organism infections, particularly for the treatment of Staphylococcal infections such as S. aureus infections including MRSA infections. ... 06/02/05 - 20050118161 - Hevein-binding monoclonal antibodies This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgE antibodies and derivatives thereof, which bind allergenic hevein with high affinity and specificity. The present invention also relates to processes for makings and engineering such hevein-binding monoclonal antibodies and to methods for using these ... ### FreshPatents.com Support |